Enhancement of Aqueous Solubility and Oral Bioavailability of Nelfinavir by Complexation with β- Cyclodextrin
AbstractPurpose: To determine if complexation with β- cyclodextrin (β-CD) increases water solubility and subsequent bioavailability of nelfinavir mesylate (NM).
Methods: Complexation of NM with β-CD in 1:1.5 molar ratio was carried out by solvent evaporation, freeze-drying and kneading methods. The complexes were characterized by Fourier transform infrared spectroscopy (FTIR). The in vitro solubility of the pure drug as well as that of the complexes was evaluated using USP type 2 apparatus. One of the drug complexes was also evaluated in vivo using Wistar rats to determine its pharmacokinetic profile.
Results: Freeze-dried NM-βCD complex was selected for in vivo studies based on its free flowing property and superior texture. The complexes prepared by the three methods all showed largely similar dissolution rate. The in vivo pharmacokinetic study of the freeze-dried complex in male Wistar rats showed significant increase in Cmax, tmax and AUC (p ≤ 0.05) compared to those of the plain drug.
Conclusion: These findings suggest that complexation of NM with β-CD is an effective and promising approach to increasing the oral bioavailability of NM.
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.